$2.56T
Total marketcap
$179.42B
Total volume
BTC 50.02%     ETH 15.82%
Dominance

Relay Therapeutics RLAY Stock

7.5 USD {{ price }} -5.660375% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
983.84M USD
LOW - HIGH [24H]
7.41 - 7.91 USD
VOLUME [24H]
1.61M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.79 USD

Relay Therapeutics Price Chart

Relay Therapeutics RLAY Financial and Trading Overview

Relay Therapeutics stock price 7.5 USD
Previous Close 11.96 USD
Open 11.79 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 11.72 - 12.96 USD
52 Week Range 9.67 - 33.06 USD
Volume 1.35M USD
Avg. Volume 1.64M USD
Market Cap 1.56B USD
Beta (5Y Monthly) 1.29903
PE Ratio (TTM) N/A
EPS (TTM) -2.79 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 27.05 USD

RLAY Valuation Measures

Enterprise Value 573.44M USD
Trailing P/E N/A
Forward P/E -3.6965318
PEG Ratio (5 yr expected) 0.03
Price/Sales (ttm) 1309.2848
Price/Book (mrq) 1.7588009
Enterprise Value/Revenue 482.691
Enterprise Value/EBITDA -1.679

Trading Information

Relay Therapeutics Stock Price History

Beta (5Y Monthly) 1.29903
52-Week Change -20.65%
S&P500 52-Week Change 20.43%
52 Week High 33.06 USD
52 Week Low 9.67 USD
50-Day Moving Average 12.28 USD
200-Day Moving Average 17.62 USD

RLAY Share Statistics

Avg. Volume (3 month) 1.64M USD
Avg. Daily Volume (10-Days) 1.21M USD
Shares Outstanding 121.61M
Float 89.95M
Short Ratio 14.72
% Held by Insiders 2.30%
% Held by Institutions 108.58%
Shares Short 21.16M
Short % of Float 22.91%
Short % of Shares Outstanding 17.39%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -29109.089%
Gross Margin 100.00%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -21.75%
Return on Equity (ttm) -37.40%

Income Statement

Revenue (ttm) 1.19M USD
Revenue Per Share (ttm) 0.01 USD
Quarterly Revenue Growth (yoy) -46.10%
Gross Profit (ttm) 1.38M USD
EBITDA -341464000 USD
Net Income Avi to Common (ttm) -322702016 USD
Diluted EPS (ttm) -2.95
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 937.8M USD
Total Cash Per Share (mrq) 7.71 USD
Total Debt (mrq) 56.75M USD
Total Debt/Equity (mrq) 6.42 USD
Current Ratio (mrq) 13.601
Book Value Per Share (mrq) 7.272

Cash Flow Statement

Operating Cash Flow (ttm) -247447008 USD
Levered Free Cash Flow (ttm) -132482000 USD

Profile of Relay Therapeutics

Country United States
State MA
City Cambridge
Address 399 Binney Street
ZIP 02139
Phone 617 370 8837
Website https://www.relaytx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 328

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Q&A For Relay Therapeutics Stock

What is a current RLAY stock price?

Relay Therapeutics RLAY stock price today per share is 7.5 USD.

How to purchase Relay Therapeutics stock?

You can buy RLAY shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Relay Therapeutics?

The stock symbol or ticker of Relay Therapeutics is RLAY.

Which industry does the Relay Therapeutics company belong to?

The Relay Therapeutics industry is Biotechnology.

How many shares does Relay Therapeutics have in circulation?

The max supply of Relay Therapeutics shares is 131.18M.

What is Relay Therapeutics Price to Earnings Ratio (PE Ratio)?

Relay Therapeutics PE Ratio is now.

What was Relay Therapeutics earnings per share over the trailing 12 months (TTM)?

Relay Therapeutics EPS is -2.79 USD over the trailing 12 months.

Which sector does the Relay Therapeutics company belong to?

The Relay Therapeutics sector is Healthcare.

Relay Therapeutics RLAY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD